Liu Rui, Ma Mingshen, Li Jing, Luan Fuxiao, Ren Tingting, Wang Nan, Ma Jianmin
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Curr Issues Mol Biol. 2024 Sep 29;46(10):10969-10990. doi: 10.3390/cimb46100652.
To investigate the differential expression of the chemokine signaling pathway in lacrimal gland benign lymphoepithelial lesion (LGBLEL) and lacrimal lymphoma, providing insights into the mechanisms underlying malignant transformation and aiding clinical differentiation. Transcriptome analysis was conducted on patients with LGBLEL, lymphoma, and orbital cavernous hemangioma (CH). Three cases of LGBLEL and three cases of lymphoma were randomly selected as control and experimental groups, respectively. A real-time quantitative polymerase chain reaction (RT-qPCR) was used to validate genes associated with the chemokine signaling pathway. Immunohistochemical (IHC) staining and quantitative Western blotting (WB) were performed for precise protein quantification. Transcriptome analysis revealed differential expression of the chemokine signaling pathway between the LGBLEL and lymphoma groups, identifying ten differentially expressed genes: , , , , , , , , , and . RT-qPCR showed that, compared to the lymphoma group, the LGBLEL group had significantly higher expression of , , , , , and ( = 0.001, <0.001, <0.001, <0.001, =0.020, <0.001, respectively) and lower expression of ( = 0.002). IHC staining and quantitative analysis confirmed significant differences in protein expression between the groups for CCL28, CCR1, CXCL17, HCK, GNB5, NRAS, and VAV2 ( = 0.003, 0.011, 0.001, 0.024, 0.005, 0.019, and 0.031, respectively). While IHC provided localization, WB offered greater precision. WB revealed that, compared to the lymphoma group, the LGBLEL group exhibited significantly higher expression of CCL28, CXCL17, HCK, GNB5, NRAS, and VAV2 ( = 0.012, 0.005, 0.009, 0.011, 0.008, and 0.003, respectively) and lower expression of CCR1 ( = 0.014). The chemokine signaling pathway plays a role in the malignant transformation of LGBLEL. The decreased expression of CCL28 and CXCL17, coupled with the increased expression of CCR1, may be linked to the progression of LGBLEL into lymphoma.
为研究趋化因子信号通路在泪腺良性淋巴上皮病变（LGBLEL）和泪腺淋巴瘤中的差异表达，深入了解恶性转化的机制并辅助临床鉴别诊断。对LGBLEL患者、淋巴瘤患者及眼眶海绵状血管瘤（CH）患者进行了转录组分析。分别随机选取3例LGBLEL患者和3例淋巴瘤患者作为对照组和实验组。采用实时定量聚合酶链反应（RT-qPCR）验证与趋化因子信号通路相关的基因。进行免疫组织化学（IHC）染色和定量蛋白质免疫印迹法（WB）以实现精确的蛋白质定量。转录组分析显示LGBLEL组和淋巴瘤组之间趋化因子信号通路存在差异表达，鉴定出10个差异表达基因： 、 、 、 、 、 、 、 、 、 。RT-qPCR结果显示，与淋巴瘤组相比，LGBLEL组 、 、 、 、 及 的表达显著更高（分别为 = 0.001、 <0.001、 <0.001、 <0.001、 =0.020、 <0.001），而 的表达更低（ = 0.002）。IHC染色和定量分析证实，两组之间CCL28、CCR1、CXCL17、HCK、GNB5、NRAS和VAV2的蛋白质表达存在显著差异（分别为 = 0.003、0.011、0.001、0.024、0.005、0.019和0.031）。虽然IHC可提供定位信息，但WB的精度更高。WB结果显示，与淋巴瘤组相比，LGBLEL组CCL28、CXCL17、HCK、GNB5、NRAS和VAV2的表达显著更高（分别为 = 0.012、0.005、0.009、0.011、0.008和0.003），而CCR1的表达更低（ = 0.014）。趋化因子信号通路在LGBLEL的恶性转化中发挥作用。CCL28和CXCL17表达降低，同时CCR1表达增加，可能与LGBLEL进展为淋巴瘤有关。
